Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | - | - | - | - | - | 0.0% | 0.0% |
| 2024 | - | - | - | - | - | 0.0% | 0.0% |
| 2023 | $3M | $-46M | $-46M | $-37M | -238.4% | -14.6% | 50.6% |
| 2022 | $3M | $-29M | $-31M | $-31M | -338.3% | -45.1% | 78.0% |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | - |
| Operating Revenue | - |
| Cost Of Revenue | - |
| Gross Profit | - |
| Operating Expense | - |
| Research And Development | - |
| Selling General And Administration | - |
| Total Expenses | - |
| Operating Income | - |
| Total Operating Income As Reported | - |
| EBITDA | - |
| Normalized EBITDA | - |
| EBIT | - |
| Interest Income | - |
| Interest Expense | - |
| Net Interest Income | - |
| Other Non Operating Income Expenses | - |
| Other Income Expense | - |
| Interest Income Non Operating | - |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | - |
| Pretax Income | - |
| Tax Provision | - |
| Tax Rate For Calcs | - |
| Tax Effect Of Unusual Items | - |
| Net Income Continuous Operations | - |
| Net Income From Continuing And Discontinued Operation | - |
| Net Income From Continuing Operation Net Minority Interest | - |
| Net Income | - |
| Net Income Common Stockholders | - |
| Net Income Including Noncontrolling Interests | - |
| Normalized Income | - |
| Diluted NI Availto Com Stockholders | - |
| Basic Average Shares | 36.91 |
| Diluted Average Shares | 36.91 |
| Reconciled Depreciation | - |
| Reconciled Cost Of Revenue | - |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Minority Interests | - |
| Special Income Charges | - |
| Other Special Charges | - |
| Gain On Sale Of Security | - |
| Depreciation Amortization Depletion Income Statement | - |
| Depreciation And Amortization In Income Statement | - |
| General And Administrative Expense | - |
| Other Gand A | - |
| Salaries And Wages | - |
| Gain On Sale Of Ppe | - |
| Insurance And Claims | - |
| Other Operating Expenses | - |
| Selling And Marketing Expense | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anteris Technologies Global Corp.this co. | AVR | $939M | - | 48.67 | -238.4% | - |
| Corvus Pharmaceuticals, Inc. | CRVS | $986M | -64.49 | 16.10 | -25.0% | -22.91 |
| InnovAge Holding Corp. | INNV | $977M | -32.24 | 4.16 | -12.9% | -102.40 |
| U.S. Physical Therapy, Inc. | USPH | $940M | 62.41 | 1.97 | 3.2% | 11.12 |
| Olema Pharmaceuticals, Inc. |
| 2021 | $6M | $-15M | $-17M | $-15M | -163.1% | - | - |
| OLMA |
| $933M |
| -5.74 |
| 1.95 |
| -33.9% |
| -4.99 |
| Nutex Health Inc. | NUTX | $930M | 13.13 | 2.82 | 21.5% | 3.81 |
| ARS Pharmaceuticals, Inc. | SPRY | $901M | -5.26 | 7.88 | -149.9% | -5.66 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Peer Median | - | -4.79 | 3.49 | -18.9% | -4.26 | |